Document is current
Any future updates will be listed below
-
Authors
Meyers, Kathrine https://orcid.org/0000-0002-8573-1958
Nguyen, Nadia
Zucker, Jason E.
Kutner, Bryan A.
Carnevale, Caroline
Castor, Delivette
Sobieszczyk, Magdalena E.
Yin, Michael T.
Golub, Sarit A.
Remien, Robert H.
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (R01MH123262, R01MH123262, P30-MH43520, K23-MH124569)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (K23AI150378)
National Institute of Allergy and Infectious Diseases (UM1AI069470)
- License Information
-
More Information
Article History
Accepted: 10 August 2022
First Online: 3 September 2022
Declarations
:
: MES has received grants to her institution from NIH, GSK and ViiV Healthcare to conduct clinical trials of Long-Acting Cabotegravir for treatment and prevention outside of the submitted work. No authors have a conflict of interest.
: N/A.
: N/A.
: N/A.
: N/A.
